ABL1 and breast cancer: Consistent with these results, treatment with the CPT1 inhibitor etomoxir (ETO, 5 μM) or CPT1A/B knockdown with CPT1A and CPT1B siRNA (20 nM) in mouse miR-142−/−BCR-ABL LSKs and human BC CD34+CD38− cells significantly suppressed FAO and OxPhos levels (Supplementary Fig. 7m–o).